Treprostinil Sodium Global Market Report 2025

The treprostinil sodium market size has grown rapidly in recent years. It will grow from $1.26 billion in 2024 to $1.39 billion in 2025 at a compound annual growth rate (CAGR) of 10.2%. The growth during the historic period can be attributed to the rising demand for treprostinil sodium, the increasing prevalence of pulmonary arterial hypertension (PAH), the growing demand for treprostinil drugs, greater awareness of respiratory health, and increased investment in healthcare infrastructure.

The treprostinil sodium market size is expected to see strong growth in the next few years. It will grow to $1.84 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to advancements in drug delivery technologies, the rising adoption of combination therapies, increasing investment in clinical trials and research activities, a growing geriatric population, and rising healthcare expenditure. Major trends include the development of improved nebulized and dry powder inhaler formulations, advancements in sustained-release formulations, the adoption of combination therapies, the creation of more stable and bioavailable oral formulations, and ongoing clinical trials exploring new therapeutic applications.

The rising incidence of pulmonary diseases is expected to drive the expansion of the treprostinil sodium market in the coming years. Pulmonary diseases affect the lungs and respiratory system, impairing breathing and oxygen circulation. Factors such as air pollution, smoking, environmental toxins, and an aging population contribute to the increasing prevalence of these conditions. Treprostinil sodium, a vasodilator, helps relax lung blood vessels, lower pressure, improve breathing, and provide flexible treatment options for pulmonary diseases. For example, in June 2024, data from the Australian Institute of Health and Welfare, an Australia-based government agency, revealed that chronic obstructive pulmonary disease (COPD) accounted for 7,691 deaths in 2022, translating to 29.6 deaths per 100,000 people and representing 4% of all fatalities. As a result, the growing number of pulmonary disease cases is fueling the demand for treprostinil sodium.

Leading companies in the treprostinil sodium market are prioritizing the development of advanced pulmonary arterial hypertension product formulations to enhance delivery methods. The formulation of pulmonary arterial hypertension (PAH) treatments involves designing medications with precise compositions to effectively manage PAH while reducing side effects. These formulations optimize the delivery of active ingredients for maximum therapeutic impact. For instance, in April 2023, Dr. Reddy's Laboratories, an India-based pharmaceutical firm, launched Treprostinil Injection in the U.S. market following approval by the Food and Drug Administration, a U.S.-based government agency. Treprostinil injection serves as a therapeutic equivalent generic version of Remodulin (treprostinil) injection, classified under prostacyclin mimetics, which are used to treat pulmonary arterial hypertension and alleviate exercise-related symptoms. It is available in vials containing 20 mg/20 mL, 50 mg/20 mL, 100 mg/20 mL, or 200 mg/20 mL.

In June 2023, Liquidia Corporation, a U.S.-based pharmaceutical company, collaborated with Pharmosa Biopharm to develop an inhaled, sustained-release formulation of treprostinil (L606) for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). This partnership seeks to leverage Liquidia’s expertise in pulmonary hypertension alongside Pharmosa’s proficiency in inhaled liposomal formulations to revolutionize treatment options in regions where inhaled treprostinil formulations are not readily available. Pharmosa Biopharm is a China-based company specializing in liposomal formulations of treprostinil.

Major players in the treprostinil sodium market are Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Dr. Reddy's Laboratories, United Therapeutics Corporation, Euroapi SA, Alembic Pharmaceuticals Ltd., Cayman Chemical, Chirogate International, Farbe Firma Pvt Ltd., Simson Pharma Limited, YONSUNG Fine Chemicals Co. Ltd., Liquidia Corporation, ChemWerth Inc., Mylan Laboratories Limited, Nuray Chemicals Private Limited, Endo International plc, LGM Pharma, Northern Therapeutics Inc, KPS Chemicals Pharmaceuticals.

North America was the largest region in the treprostinil sodium market in 2024. The regions covered in treprostinil sodium report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Treprostinil Sodium market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Treprostinil sodium is a synthetic prostacyclin (PGI₂) analogue used to treat pulmonary arterial hypertension (PAH) by improving exercise capacity and alleviating symptoms. It works by promoting vasodilation, inhibiting platelet aggregation, and reducing vascular remodeling, thereby lowering pulmonary pressure, enhancing blood flow, and slowing disease progression to improve the quality of life.

The main product types of treprostinil sodium include injectable, inhalable, and oral formulations. The injectable form is administered directly via syringe or needle to improve exercise capacity and reduce symptoms in PAH patients. Treprostinil sodium is used for various applications, including pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, and other related conditions. It is distributed through multiple channels, such as hospitals, specialty clinics, online pharmacies, and retail pharmacies.

The treprostinil sodium market research report is one of a series of new reports that provides treprostinil sodium market statistics, including the treprostinil sodium industry global market size, regional shares, competitors with the treprostinil sodium market share, detailed treprostinil sodium market segments, market trends, and opportunities, and any further data you may need to thrive in the treprostinil sodium industry. This treprostinil sodium market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The treprostinil sodium market consists of sales of nasal spray formulation, buccal or lingual tablet, and nebulized solution. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.